Literature DB >> 16736232

The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice.

M B H Youdim1, E Grünblatt, S Mandel.   

Abstract

In MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and 6-hydroxydopamine induced dopaminergic neurotoxicity and Parkinson's disease iron accumulates in substantia nigra pars compacta which has been suggested to participate in oxidative stress induced neurodegeneration. Pretreatment with iron chelators desferal, clioquinol, VK-28 and M30 are neuroprotective in both models. To determine the specificity of chelation neuroprotective activity we have examined the effect of D-penicillamine, a relatively specific copper chelator, in the mice model of MPTP-induced dopamine depletion. Our studies show that D-penicillamine, employed for removal of copper in Wilson disease is relatively weak in preventing dopaminergic neurotoxicity induced by MPTP, as compared to iron chelators previously studied. The results indicate that for prevention of MPTP-induced dopamine depletion and dopamine neurodegeneration, iron rather than copper chelation may be more effective and specific.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16736232     DOI: 10.1007/s00702-006-0499-1

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  46 in total

1.  MRI, brain iron and experimental Parkinson's disease.

Authors:  S Hall; J N Rutledge; T Schallert
Journal:  J Neurol Sci       Date:  1992-12       Impact factor: 3.181

2.  Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.

Authors:  Shunit Gal; Hailin Zheng; Mati Fridkin; Moussa B H Youdim
Journal:  J Neurochem       Date:  2005-10       Impact factor: 5.372

Review 3.  Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment.

Authors:  B Halliwell
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys.

Authors:  H Mochizuki; H Imai; K Endo; K Yokomizo; Y Murata; N Hattori; Y Mizuno
Journal:  Neurosci Lett       Date:  1994-02-28       Impact factor: 3.046

5.  Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.

Authors:  Moussa B H Youdim; Galia Stephenson; Dorit Ben Shachar
Journal:  Ann N Y Acad Sci       Date:  2004-03       Impact factor: 5.691

6.  Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.

Authors:  J Sian; D T Dexter; A J Lees; S Daniel; Y Agid; F Javoy-Agid; P Jenner; C D Marsden
Journal:  Ann Neurol       Date:  1994-09       Impact factor: 10.422

7.  The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons.

Authors:  D Ben-Shachar; G Eshel; J P Finberg; M B Youdim
Journal:  J Neurochem       Date:  1991-04       Impact factor: 5.372

8.  [Fe and Cu content in the liver, spleen, kidney and heart of growing rats with variable Fe and Cu supply].

Authors:  E Grassmann; M Kirchgessner; J J Kim
Journal:  Z Ernahrungswiss       Date:  1983-06

9.  Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain.

Authors:  E Sofic; P Riederer; H Heinsen; H Beckmann; G P Reynolds; G Hebenstreit; M B Youdim
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

10.  Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain.

Authors:  T A Seaton; P Jenner; C D Marsden
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

View more
  9 in total

Review 1.  Iron chelation and neuroprotection in neurodegenerative diseases.

Authors:  Xuping Li; Joseph Jankovic; Weidong Le
Journal:  J Neural Transm (Vienna)       Date:  2010-12-16       Impact factor: 3.575

2.  Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

Authors:  Shunit Gal; Hailin Zheng; Mati Fridkin; Moussa B H Youdim
Journal:  Neurotox Res       Date:  2009-07-16       Impact factor: 3.911

3.  Chelators in the treatment of iron accumulation in Parkinson's disease.

Authors:  Ross B Mounsey; Peter Teismann
Journal:  Int J Cell Biol       Date:  2012-06-13

4.  PET imaging a MPTP-induced mouse model of Parkinson's disease using the fluoropropyl-dihydrotetrabenazine analog [18F]-DTBZ (AV-133).

Authors:  James S Toomey; Shilpa Bhatia; La'Wanda T Moon; Elysse A Orchard; Kerrie H Tainter; Stephen J Lokitz; Tracee Terry; J Michael Mathis; Andrew D Penman
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

5.  Rapid copper acquisition by developing murine mesothelioma: decreasing bioavailable copper slows tumor growth, normalizes vessels and promotes T cell infiltration.

Authors:  Andrew Crowe; Connie Jackaman; Katie M Beddoes; Belinda Ricciardo; Delia J Nelson
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

Review 6.  Copper and copper proteins in Parkinson's disease.

Authors:  Sergio Montes; Susana Rivera-Mancia; Araceli Diaz-Ruiz; Luis Tristan-Lopez; Camilo Rios
Journal:  Oxid Med Cell Longev       Date:  2014-01-08       Impact factor: 6.543

Review 7.  Copper Ions and Parkinson's Disease: Why Is Homeostasis So Relevant?

Authors:  Marco Bisaglia; Luigi Bubacco
Journal:  Biomolecules       Date:  2020-01-29

8.  Iron overload resulting from the chronic oral administration of ferric citrate induces parkinsonism phenotypes in middle-aged mice.

Authors:  Chao Huang; Wenjing Ma; Qihui Luo; Liangqin Shi; Yu Xia; Chengjie Lao; Wentao Liu; Yuanfeng Zou; Anchun Cheng; Riyi Shi; Zhengli Chen
Journal:  Aging (Albany NY)       Date:  2019-11-07       Impact factor: 5.682

Review 9.  Iron deposits in the chronically inflamed central nervous system and contributes to neurodegeneration.

Authors:  Hjalte Holm Andersen; Kasper Bendix Johnsen; Torben Moos
Journal:  Cell Mol Life Sci       Date:  2013-11-12       Impact factor: 9.261

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.